TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05191693

Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
Study: NCT04533386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component intervention strategy
Description: Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
Study: NCT04332107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants will be shipped a single 1.2 g dose of oral azithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants will be shipped a dose of matching placebo
Study: NCT00411671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg By Mouth Twice Daily for 28 Days.
Study: NCT00883961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
Study: NCT02944214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
Study: NCT03951272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant
Description: Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant
Description: Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
Study: NCT02042521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactose Placebo
Description: This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
Study: NCT03362294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 40mg once monthly
Description: Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 25mg once monthly
Description: Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
Study: NCT03176628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis
Description: NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule(s)
Study: NCT03681925

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutrition Literacy Assessment Instrument (NLit)
Description: The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
Study: NCT02157181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2CdA +/- Rituximab
Description: Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
Study: NCT02042521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactose Placebo
Description: This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
Study: NCT00669214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Study: NCT00754377

Intervention type: OTHER
Intervention: PBLI Curriculum
Description: PBLI curriculum was offered on alternate rotations
Study: NCT04194268

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion
Description: 12 x 4 Gy (RBE)
Study: NCT00726414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 2 x 324 mg Capsules
Description: Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 2 x 324 mg Capsules
Description: Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
Study: NCT01635231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: hypertonic saline 3.0% 7 ml/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic saline
Description: hypertonic saline 3.0% 7 ml/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: hypertonic saline 3.0% 7 ml/kg
Study: NCT01165983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg tablet, taken orally for 12 weeks daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150mg tablet, taken orally for 12 weeks daily
Study: NCT00086047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: 8 weekly sessions of behavioral treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 8 weekly sessions of fibromyalgia education
Study: NCT04039958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soviredia
Description: Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (first dose)
Description: Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (Second dose)
Description: Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study: NCT03202407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium acetate and sevelamer hydrochloride
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate and sevelamer hydrochloride
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
Study: NCT04494906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive stepping exercise
Description: An exercise intervention based on the principle of square stepping exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square stepping exercise
Description: Square stepping exercise
Study: NCT02818972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RelayPro
Description: Endovascular treatment with investigational device.
Study: NCT03571555

Intervention type: BEHAVIORAL
Intervention: Sentebale Psychosocial Programme
Description: Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.

Intervention type: BEHAVIORAL
Intervention: Sentebale Psychosocial Programme
Description: Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
Study: NCT02137824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor elevation
Study: NCT04627155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres
Study: NCT01615016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive endotracheal surfactant application
Description: What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimally invasive endotracheal surfactant application
Description: What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26
Study: NCT02274792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
Study: NCT04110782

Intervention type: OTHER
Intervention: Radium223
Description: 55 kBq/ Kg
Study: NCT04479332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation and cardiopulmonary resuscitation
Description: Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation and cardiopulmonary resuscitation
Description: Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
Study: NCT02534415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal dressing material
Description: Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% Hyaluronic acid gel
Description: 0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Hyaluronic acid gel
Description: 0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
Study: NCT00981461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HairMax LaserComb
Description: Device application 3 times week, for 26 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Device
Description: Device application 3 times week, for 26 weeks
Study: NCT01008943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells
Description: Urethral injection of autologous muscle-derived cells
Study: NCT00936702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT01636635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
Study: NCT03371693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRS
Description: cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.

Intervention type: DEVICE
Group type: OTHER
Intervention: CRS
Description: cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVCT
Description: platinum-based intravenous chemotherapy

Intervention type: DEVICE
Group type: OTHER
Intervention: IVCT
Description: platinum-based intravenous chemotherapy
Study: NCT03518294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
Study: NCT02089919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study: NCT02889627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota suspension
Description: The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
Study: NCT02287896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROLEDUMAB
Description: See Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROLEDUMAB
Description: See Arm description
Study: NCT00617682

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNCRM9
Description: 0.5 mL IM at 30-35 wks gestation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
Study: NCT01125215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% capsaicin nanoparticle cream
Description: 0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
Study: NCT01310322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Study: NCT03852797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin solution, 20nM concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin solution, 20nM concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin solution, 20nM concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine in solution, 10-4M to 10-7M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine in solution, 10-4M to 10-7M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol in solution, 10-4M to 10-7M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol in solution, 10-4M to 10-7M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate in solution, 10-4M to 10-7M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate in solution, 10-4M to 10-7M
Study: NCT04089540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New intubation method

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional intubation method
Study: NCT02699944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Vest Optimization
Description: As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
Study: NCT02963493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide (Melflufen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
Study: NCT02135575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning
Description: After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinning
Description: After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
Study: NCT03144180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-cup
Description: This technology is a different way of collecting umbilical cord blood.
Study: NCT00660062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 20 mg daily dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 30 mg daily dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline
Description: 100 mg daily dosage
Study: NCT03663595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 1
Description: Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 2
Description: Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
Study: NCT01173302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine, manufactured by ChengDa
Description: 1 dose before the antibody is tested